Interpreting the Survival Benefit From Neoadjuvant Chemoradiotherapy Before Surgery for Locally Advanced Squamous Cell Carcinoma of the Esophagus

Affiliations

Comment

Zachary R McCaw et al. J Clin Oncol. 2019.

. 2019 Apr 20;37(12):1032-1033.

doi: 10.1200/JCO.18.01164. Epub 2019 Mar 6.

¹ Zachary R. McCaw, AM, and Lee-Jen Wei, PhD, Harvard TH Chan School of Public Health, Boston, MA.

No abstract available

Comment in

Reply to Z. McCaw and L-J. Wei.
Li J, Liu Q, Yang H, Fu J. Li J, et al. J Clin Oncol. 2019 Apr 20;37(12):1034. doi: 10.1200/JCO.18.01829. Epub 2019 Mar 6. J Clin Oncol. 2019. PMID: 30840523 No abstract available.

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Yang H, et al. J Clin Oncol. 2018 Sep 20;36(27):2796-2803. doi: 10.1200/JCO.2018.79.1483. Epub 2018 Aug 8. J Clin Oncol. 2018. PMID: 30089078 Free PMC article. Clinical Trial.